Home > Oncology > ESMO 2022 > Addition of pembrolizumab to lenvatinib does not improve OS in advanced HCC

Addition of pembrolizumab to lenvatinib does not improve OS in advanced HCC

Presented By
Dr Richard Finn, David Geffen School of Medicine, CA, USA
Conference
ESMO 2022
Trial
Phase 3, LEAP-002
Final analysis of the phase 3 LEAP-002 study did not demonstrate an overall survival (OS) benefit of addition of pembrolizumab to first-line lenvatinib in patients with advanced hepatocellular carcinoma (aHCC). However, the study supports the role of lenvatinib as a standard first-line treatment for aHCC. Systemic therapy options for advanced stages of HCC have rapidly expanded in the past years. For example, the REFLECT study demonstrated lenvatinib in first-line to be non-inferior to sorafenib regarding OS [1]. In addition, pembrolizumab has shown favourable results as a second-line therapy [2,3]. In a phase 1 study, the combination of lenvatinib plus pembrolizumab demonstrated promising anti-tumour activity and manageable safety as first-line therapy in unresectable HCC [4]. The global, randomised, double-blind, phase 3 LEAP-002 study (NCT03713593) evaluated th...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on